Aptose Biosciences (NASDAQ:APTO) Shares Pass Below Fifty Day Moving Average – Time to Sell?

Aptose Biosciences Inc. (NASDAQ:APTO) (TSE:APS) shares passed below its fifty day moving average during trading on Tuesday . The stock has a fifty day moving average of $0.26 and traded as low as $0.22. Aptose Biosciences shares last traded at $0.23, with a volume of 731,786 shares traded.

Wall Street Analyst Weigh In

A number of research analysts recently commented on APTO shares. StockNews.com initiated coverage on Aptose Biosciences in a research note on Wednesday. They issued a “hold” rating for the company. HC Wainwright reissued a “buy” rating and issued a $2.00 target price on shares of Aptose Biosciences in a report on Tuesday, December 10th.

Aptose Biosciences Trading Down 0.2 %

The company has a market cap of $13.67 million, a P/E ratio of -0.08 and a beta of 0.87. The company has a 50 day moving average price of $0.26 and a 200-day moving average price of $0.42.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Aptose Biosciences stock. Sigma Planning Corp lifted its stake in shares of Aptose Biosciences Inc. (NASDAQ:APTO) (TSE:APS) by 71.3% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 401,750 shares of the biotechnology company’s stock after purchasing an additional 167,282 shares during the quarter. Sigma Planning Corp owned 2.22% of Aptose Biosciences worth $165,000 as of its most recent filing with the Securities and Exchange Commission. 26.62% of the stock is owned by hedge funds and other institutional investors.

About Aptose Biosciences

Aptose Biosciences Inc, a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies.